Plasma transforming growth factor β1 as a predictor of radiation pneumonitis

Mitchell S. Anscher, Feng Ming Kong, Katrina Andrews, Robert Clough, Lawrence B. Marks, Gunilla Bentel, Randy L. Jirtle

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Purpose: To investigate prospectively the utility of plasma transforming growth factor β1 (TGFβ1) as a marker for the development of symptomatic radiation pneumonitis. Materials and Methods: Seventy-three patients with lung cancer treated with curative intent are reported herein. Plasma TGFβ1 samples were obtained before, weekly during, and at each follow-up after radiation therapy (RT). TGFβ1 was extracted using an acid/ethanol method. An enzyme-linked immunosorbent assay was used to quantify plasma TGFβ1 concentrations. The TGFβ1 level at the end of RT was considered 'normal', if it was both ≤ 7.5 ng/ml and less than the pretreatment value. All patients were followed for at least 6 months, unless symptomatic pneumonitis developed sooner. Pneumonitis was defined by National Cancer Institute (NCI) common toxicity criteria. Results: Fifteen of the 73 patients (21%) developed symptomatic pneumonitis and the remaining 58 (79%) did not. A normal plasma TGFβ1 by the end of RT, as defined above, was more common in patients who did not develop pneumonitis. A return of the plasma TGFβ1 to normal accurately identified patients who would not develop pneumonitis with both a sensitivity and positive predictive value of 90%. Conclusion: Plasma TGFβ1 levels appear to be a useful means to identify patients at low risk for the development of pneumonitis from thoracic RT. Thus, monitoring of plasma TGFβ1 levels may identify candidates for dose escalation studies in the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)1029-1035
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume41
Issue number5
DOIs
StatePublished - Jul 15 1998

Fingerprint

Radiation Pneumonitis
Transforming Growth Factors
Pneumonia
radiation
predictions
radiation therapy
Radiotherapy
cancer
lungs
Lung Neoplasms
National Cancer Institute (U.S.)
toxicity
pretreatment
markers
enzymes
ethyl alcohol
Ethanol
Thorax
Enzyme-Linked Immunosorbent Assay
dosage

Keywords

  • Complications
  • Fibrosis
  • Growth factors
  • Lung cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Anscher, M. S., Kong, F. M., Andrews, K., Clough, R., Marks, L. B., Bentel, G., & Jirtle, R. L. (1998). Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. International Journal of Radiation Oncology Biology Physics, 41(5), 1029-1035. https://doi.org/10.1016/S0360-3016(98)00154-0

Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. / Anscher, Mitchell S.; Kong, Feng Ming; Andrews, Katrina; Clough, Robert; Marks, Lawrence B.; Bentel, Gunilla; Jirtle, Randy L.

In: International Journal of Radiation Oncology Biology Physics, Vol. 41, No. 5, 15.07.1998, p. 1029-1035.

Research output: Contribution to journalArticle

Anscher, MS, Kong, FM, Andrews, K, Clough, R, Marks, LB, Bentel, G & Jirtle, RL 1998, 'Plasma transforming growth factor β1 as a predictor of radiation pneumonitis', International Journal of Radiation Oncology Biology Physics, vol. 41, no. 5, pp. 1029-1035. https://doi.org/10.1016/S0360-3016(98)00154-0
Anscher, Mitchell S. ; Kong, Feng Ming ; Andrews, Katrina ; Clough, Robert ; Marks, Lawrence B. ; Bentel, Gunilla ; Jirtle, Randy L. / Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. In: International Journal of Radiation Oncology Biology Physics. 1998 ; Vol. 41, No. 5. pp. 1029-1035.
@article{c1d1c85faa984f6ba214c180ffd6d3de,
title = "Plasma transforming growth factor β1 as a predictor of radiation pneumonitis",
abstract = "Purpose: To investigate prospectively the utility of plasma transforming growth factor β1 (TGFβ1) as a marker for the development of symptomatic radiation pneumonitis. Materials and Methods: Seventy-three patients with lung cancer treated with curative intent are reported herein. Plasma TGFβ1 samples were obtained before, weekly during, and at each follow-up after radiation therapy (RT). TGFβ1 was extracted using an acid/ethanol method. An enzyme-linked immunosorbent assay was used to quantify plasma TGFβ1 concentrations. The TGFβ1 level at the end of RT was considered 'normal', if it was both ≤ 7.5 ng/ml and less than the pretreatment value. All patients were followed for at least 6 months, unless symptomatic pneumonitis developed sooner. Pneumonitis was defined by National Cancer Institute (NCI) common toxicity criteria. Results: Fifteen of the 73 patients (21{\%}) developed symptomatic pneumonitis and the remaining 58 (79{\%}) did not. A normal plasma TGFβ1 by the end of RT, as defined above, was more common in patients who did not develop pneumonitis. A return of the plasma TGFβ1 to normal accurately identified patients who would not develop pneumonitis with both a sensitivity and positive predictive value of 90{\%}. Conclusion: Plasma TGFβ1 levels appear to be a useful means to identify patients at low risk for the development of pneumonitis from thoracic RT. Thus, monitoring of plasma TGFβ1 levels may identify candidates for dose escalation studies in the treatment of lung cancer.",
keywords = "Complications, Fibrosis, Growth factors, Lung cancer, Radiation therapy",
author = "Anscher, {Mitchell S.} and Kong, {Feng Ming} and Katrina Andrews and Robert Clough and Marks, {Lawrence B.} and Gunilla Bentel and Jirtle, {Randy L.}",
year = "1998",
month = "7",
day = "15",
doi = "10.1016/S0360-3016(98)00154-0",
language = "English (US)",
volume = "41",
pages = "1029--1035",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Plasma transforming growth factor β1 as a predictor of radiation pneumonitis

AU - Anscher, Mitchell S.

AU - Kong, Feng Ming

AU - Andrews, Katrina

AU - Clough, Robert

AU - Marks, Lawrence B.

AU - Bentel, Gunilla

AU - Jirtle, Randy L.

PY - 1998/7/15

Y1 - 1998/7/15

N2 - Purpose: To investigate prospectively the utility of plasma transforming growth factor β1 (TGFβ1) as a marker for the development of symptomatic radiation pneumonitis. Materials and Methods: Seventy-three patients with lung cancer treated with curative intent are reported herein. Plasma TGFβ1 samples were obtained before, weekly during, and at each follow-up after radiation therapy (RT). TGFβ1 was extracted using an acid/ethanol method. An enzyme-linked immunosorbent assay was used to quantify plasma TGFβ1 concentrations. The TGFβ1 level at the end of RT was considered 'normal', if it was both ≤ 7.5 ng/ml and less than the pretreatment value. All patients were followed for at least 6 months, unless symptomatic pneumonitis developed sooner. Pneumonitis was defined by National Cancer Institute (NCI) common toxicity criteria. Results: Fifteen of the 73 patients (21%) developed symptomatic pneumonitis and the remaining 58 (79%) did not. A normal plasma TGFβ1 by the end of RT, as defined above, was more common in patients who did not develop pneumonitis. A return of the plasma TGFβ1 to normal accurately identified patients who would not develop pneumonitis with both a sensitivity and positive predictive value of 90%. Conclusion: Plasma TGFβ1 levels appear to be a useful means to identify patients at low risk for the development of pneumonitis from thoracic RT. Thus, monitoring of plasma TGFβ1 levels may identify candidates for dose escalation studies in the treatment of lung cancer.

AB - Purpose: To investigate prospectively the utility of plasma transforming growth factor β1 (TGFβ1) as a marker for the development of symptomatic radiation pneumonitis. Materials and Methods: Seventy-three patients with lung cancer treated with curative intent are reported herein. Plasma TGFβ1 samples were obtained before, weekly during, and at each follow-up after radiation therapy (RT). TGFβ1 was extracted using an acid/ethanol method. An enzyme-linked immunosorbent assay was used to quantify plasma TGFβ1 concentrations. The TGFβ1 level at the end of RT was considered 'normal', if it was both ≤ 7.5 ng/ml and less than the pretreatment value. All patients were followed for at least 6 months, unless symptomatic pneumonitis developed sooner. Pneumonitis was defined by National Cancer Institute (NCI) common toxicity criteria. Results: Fifteen of the 73 patients (21%) developed symptomatic pneumonitis and the remaining 58 (79%) did not. A normal plasma TGFβ1 by the end of RT, as defined above, was more common in patients who did not develop pneumonitis. A return of the plasma TGFβ1 to normal accurately identified patients who would not develop pneumonitis with both a sensitivity and positive predictive value of 90%. Conclusion: Plasma TGFβ1 levels appear to be a useful means to identify patients at low risk for the development of pneumonitis from thoracic RT. Thus, monitoring of plasma TGFβ1 levels may identify candidates for dose escalation studies in the treatment of lung cancer.

KW - Complications

KW - Fibrosis

KW - Growth factors

KW - Lung cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0032527651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032527651&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(98)00154-0

DO - 10.1016/S0360-3016(98)00154-0

M3 - Article

VL - 41

SP - 1029

EP - 1035

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -